Hydrocortisone for BPD Eligibility Form in A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22-26 Months of Age in Intubated Infants <30 Weeks Gestation Age

Hydrocortisone for BPD Eligibility Form, CSV. Captures trial eligibility data.
Study Description
The Hydrocortisone and Extubation study tested the safety and efficacy of a 10-day course of hydrocortisone for infants who were less than 30 weeks estimated gestational age and who were intubated at 14-28 days of life. Infants were randomized to receive hydrocortisone or placebo. The study determined that hydrocortisone treatment starting on postnatal day 14 to 28 did not result in substantially higher survival without moderate or severe bronchopulmonary dysplasia than placebo. Survival without moderate or severe neurodevelopmental impairment did not differ substantially between the two groups. Infants inborn at a network clinical center who were between 14-28 postnatal days who were <30 weeks estimated gestational age and had received ≥ 7 days of mechanical ventilation and were receiving mechanical ventilation through an endotrachel tube.

氢化可的松用于支气管肺发育不良（Bronchopulmonary Dysplasia, BPD）入组资格表数据集，格式为CSV。该数据集收录了临床试验的入组资格相关数据。

研究概况
「氢化可的松与拔管」临床试验评估了10天疗程氢化可的松针对胎龄预估小于30周、且在出生后14~28天接受气管插管的婴儿的安全性与有效性。研究对象被随机分配至氢化可的松组或安慰剂组。
本研究结果显示，于出生后14~28天启动氢化可的松治疗，相较于安慰剂组，并未显著提升无中重度支气管肺发育不良（BPD）的存活率；两组间无中重度神经发育障碍的存活率亦无显著差异。
本研究的入组标准为：来自协作网络临床中心、出生后14~28天、胎龄预估小于30周、已接受≥7天机械通气且当前经气管导管实施机械通气的婴儿。